Comments on: FDA provides “explanation” for Sanjay Kaul’s absence http://cardiobrief.org/2009/02/11/fda-provides-explanation-for-sanjay-kauls-absence/ One-stop source for cardiology news and links Sun, 20 May 2012 04:30:15 +0000 hourly 1 http://wordpress.com/ By: Oops, She Did It Again! FDA Disinvites Another Advisor « CardioBrief http://cardiobrief.org/2009/02/11/fda-provides-explanation-for-sanjay-kauls-absence/#comment-7136 Thu, 08 Dec 2011 12:50:39 +0000 http://cardiobrief.org/?p=510#comment-7136 [...] without explanation from the prasugrel (Efient, Lilly) advisory panel (as recounted here, here, here, and here), provoking considerable controversy and two congressional [...]

]]> By: Chronology of Prasugrel Controversy « CardioBrief http://cardiobrief.org/2009/02/11/fda-provides-explanation-for-sanjay-kauls-absence/#comment-106 Mon, 23 Feb 2009 16:55:13 +0000 http://cardiobrief.org/?p=510#comment-106 [...] http://cardiobrief.org/2009/02/11/fda-provides-explanation-for-sanjay-kauls-absence/ [...]

]]> By: The Uninvited (part 2): FDA offers more detailed explanation for Kaul’s absence on prasugrel committee « CardioBrief http://cardiobrief.org/2009/02/11/fda-provides-explanation-for-sanjay-kauls-absence/#comment-63 Thu, 19 Feb 2009 18:14:39 +0000 http://cardiobrief.org/?p=510#comment-63 [...] Click here to read our previous post about the FDA’s explanation. [...]

]]>